Karyopharm Therapeutics (FRA:25K) Inventories, Finished Goods : €0.6 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Karyopharm Therapeutics Inventories, Finished Goods?

Karyopharm Therapeutics's quarterly finished goods declined from Sep. 2023 (€0.7 Mil) to Dec. 2023 (€0.7 Mil) and declined from Dec. 2023 (€0.7 Mil) to Mar. 2024 (€0.6 Mil).

Karyopharm Therapeutics's annual finished goods increased from Dec. 2021 (€0.4 Mil) to Dec. 2022 (€0.9 Mil) but then declined from Dec. 2022 (€0.9 Mil) to Dec. 2023 (€0.7 Mil).

Karyopharm Therapeutics Inventories, Finished Goods Historical Data

The historical data trend for Karyopharm Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics Inventories, Finished Goods Chart

Karyopharm Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

0.07

0.37

0.92

0.70

Karyopharm Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventories, Finished Goods	Get a 7-Day Free Trial															0.87	0.78	0.71	0.70	0.58

Karyopharm Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Karyopharm Therapeutics (FRA:25K) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (FRA:25K) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

KPTI:USA

Address

85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459

Website

https://www.karyopharm.com

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Karyopharm Therapeutics (FRA:25K) Headlines

No Headlines